News for Design Therapeutics, Inc. (DSGN)

CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( DSGN), a clinical-stage biotechnology company developing treatments for serio

Utah-based Sintx Technologies, Inc. (SINT) is up over 87 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 f...

Shares of GCL Global Holdings Ltd GCL rose sharply in today’s pre-market trading. GCL and RF Acquisition Corp. disclosed the successful completion of their b...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results in Friedreich's ataxia. See more here.

Israel-based Silexion Therapeutics Corp (SLXN), a biopharmaceutical company is up over 65 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Sangamo Therapeutics, Inc. SGMO fell sharp...

Shares of Cemtrex, Inc. CETX rose sharply in today's pre-market trading after the company posted stronger-than-expected sales for the fourth quarter, reporting ...

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Thursday. Shares of Lamb Weston Holdings, Inc. LW fell sharply in ...

Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading. Astellas and Sangamo Therapeutics disclosed Capsid license agreement to d...

**media[469577,469578]**

Design Therapeutics stock soars to 52-week high of $6.91

Friedreich’s Ataxia Drugs Gaining Prominence Amid Several Government Initiatives Focused on Rare Disease Research....

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with...

FDA's removal of partial clinical hold on nomlabofusp for FA treatment now puts Larimar on a smoother path to success. Read my analysis of LRMR stock here.

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded down 0.82% to 35,017.95 while the NASDAQ fell 0.77% to 13,682.54. The S&P 500, also fell, dropping, 0.87% to 4,450.59.

GuruFocus Article or News written by insider and the topic is about:

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.55%